These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 8078734)

  • 21. Pneumocystis carinii severe pneumonia among human immunodeficiency virus-infected children in Thailand: the effect of a primary prophylaxis strategy.
    Chokephaibulkit K; Wanachiwanawin D; Chearskul S; Wanprapa N; Unganont K; Tantinikorn W; Udompunthurak S
    Pediatr Infect Dis J; 1999 Feb; 18(2):147-52. PubMed ID: 10048687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of trimethoprim-sulfamethoxazole for the prevention of bacterial infections in a randomized prophylaxis trial of patients with advanced HIV infection.
    DiRienzo AG; van Der Horst C; Finkelstein DM; Frame P; Bozzette SA; Tashima KT
    AIDS Res Hum Retroviruses; 2002 Jan; 18(2):89-94. PubMed ID: 11839141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of low-dose trimethoprim-sulfamethoxazole thrice weekly for primary and secondary prophylaxis of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients.
    Stein DS; Stevens RC; Terry D; Laizure SC; Palte S; Lancaster DJ; Weems JJ; Williams CL
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1705-9. PubMed ID: 1952835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
    Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
    N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study.
    Saah AJ; Hoover DR; Peng Y; Phair JP; Visscher B; Kingsley LA; Schrager LK
    JAMA; 1995 Apr; 273(15):1197-202. PubMed ID: 7707627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. National Pediatric and Family HIV Resource Center and National Center for Infectious Diseases, Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 1995 Apr; 44(RR-4):1-11. PubMed ID: 7565543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis.
    Fox BC; Sollinger HW; Belzer FO; Maki DG
    Am J Med; 1990 Sep; 89(3):255-74. PubMed ID: 2118307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective, double-blind, placebo-controlled trial of i.v. immunoglobulin and trimethoprim-sulfamethoxazole in children with recurrent respiratory tract infections.
    Nydahl-Persson K; Petterson A; Fasth A
    Acta Paediatr; 1995 Sep; 84(9):1007-9. PubMed ID: 8652950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group.
    El-Sadr WM; Murphy RL; Yurik TM; Luskin-Hawk R; Cheung TW; Balfour HH; Eng R; Hooton TM; Kerkering TM; Schutz M; van der Horst C; Hafner R
    N Engl J Med; 1998 Dec; 339(26):1889-95. PubMed ID: 9862944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group.
    Schneider MM; Hoepelman AI; Eeftinck Schattenkerk JK; Nielsen TL; van der Graaf Y; Frissen JP; van der Ende IM; Kolsters AF; Borleffs JC
    N Engl J Med; 1992 Dec; 327(26):1836-41. PubMed ID: 1360145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Experience with the use of immune intravenous immunoglobulin in symptomatic children with human immunodeficiency virus infection].
    Jiménez E; Carrer MT; Pérez Dieppa I; Ortiz L; Fernández M
    Bol Asoc Med P R; 1991 Dec; 83(12):538-42. PubMed ID: 1811606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.
    Bozzette SA; Finkelstein DM; Spector SA; Frame P; Powderly WG; He W; Phillips L; Craven D; van der Horst C; Feinberg J
    N Engl J Med; 1995 Mar; 332(11):693-9. PubMed ID: 7854375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Severe bacterial infections after prophylactic suppression of Pneumocystis carinii in HIV infected patients after CD4 lymphocyte recovery].
    Boix V; Murcia JM; Merino E; Portilla J
    Med Clin (Barc); 2002 Jun; 118(20):796-7. PubMed ID: 12049699
    [No Abstract]   [Full Text] [Related]  

  • 34. Randomized controlled trial of short-term withdrawal of i.v. immunoglobulin therapy for selected children with human immunodeficiency virus infection.
    Grisaru-Soen G; Lau W; Arneson C; Louch D; Bitnun A; Stephens D; Read SE; King SM
    Pediatr Int; 2007 Dec; 49(6):972-7. PubMed ID: 18045306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial.
    Chintu C; Bhat GJ; Walker AS; Mulenga V; Sinyinza F; Lishimpi K; Farrelly L; Kaganson N; Zumla A; Gillespie SH; Nunn AJ; Gibb DM;
    Lancet; 2004 Nov 20-26; 364(9448):1865-71. PubMed ID: 15555666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group.
    Thea DM; Lambert G; Weedon J; Matheson PB; Abrams EJ; Bamji M; Straus WL; Thomas PA; Krasinski K; Heagarty M
    Pediatrics; 1996 Jan; 97(1):59-64. PubMed ID: 8545225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discontinuation of secondary prophylaxis for Pneumocystis pneumonia in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy.
    Esposito S; Bojanin J; Porta A; Cesati L; Gualtieri L; Principi N
    Pediatr Infect Dis J; 2005 Dec; 24(12):1117-20. PubMed ID: 16371882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylaxis for Pneumocystis carinii pneumonia in patients infected with human immunodeficiency virus.
    Kovacs JA; Masur H
    Clin Infect Dis; 1992 May; 14(5):1005-9. PubMed ID: 1350925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality standard for the prophylaxis of Pneumocystis carinii pneumonia in infants and children born to women infected with human immunodeficiency virus.
    Wilfert CM; Masur H; Gross PA; Kaplan JE; Holmes KK; Phair JP; Simonds RJ
    Clin Infect Dis; 1995 Aug; 21 Suppl 1():S132-3. PubMed ID: 8547506
    [No Abstract]   [Full Text] [Related]  

  • 40. Failure of intravenous pentamidine prophylaxis for Pneumocystis carinii pneumonia.
    Weintrub PS; Wara DW; Duliege AM
    J Pediatr; 1993 Jan; 122(1):163-4. PubMed ID: 8419606
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.